Stockscreener 앱 받기
1.16
2.65%
0.03
시간 외 거래:
1.14
-0.02
-1.72%
전일 마감가:
$1.13
열려 있는:
$1.12
하루 거래량:
559.79K
Relative Volume:
1.05
시가총액:
$71.83M
수익:
$248.00K
순이익/손실:
$-113.22M
주가수익비율:
-0.6299
EPS:
-1.8416
순현금흐름:
$-98.81M
1주 성능:
+4.50%
1개월 성능:
+10.48%
6개월 성능:
-10.08%
1년 성능:
-28.83%
1일 변동 폭
$1.11
$1.185
1주일 범위
$1.0932
$1.185
52주 변동 폭
$1.02
$1.95
Pliant Therapeutics Inc Stock (PLRX) Company Profile
명칭
Pliant Therapeutics Inc
전화
650-481-6770
주소
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare PLRX vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.16 | 69.35M | 248.00K | -113.22M | -98.81M | -1.8416 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-03-04 | 재개 | Cantor Fitzgerald | Neutral |
| 2025-03-04 | 다운그레이드 | Needham | Buy → Hold |
| 2025-03-03 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-03-03 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-02-10 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2025-02-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-02-10 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-02-10 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-02-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-02-10 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-10 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-05-18 | 개시 | Canaccord Genuity | Buy |
| 2023-04-13 | 개시 | Robert W. Baird | Outperform |
| 2022-12-14 | 개시 | Stifel | Buy |
| 2022-12-07 | 개시 | JP Morgan | Overweight |
| 2022-09-01 | 개시 | Citigroup | Buy |
| 2022-07-20 | 개시 | SVB Leerink | Outperform |
| 2022-05-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-12-10 | 개시 | Oppenheimer | Outperform |
| 2021-11-24 | 개시 | RBC Capital Mkts | Outperform |
| 2021-11-03 | 개시 | H.C. Wainwright | Buy |
| 2021-04-20 | 개시 | BTIG Research | Buy |
| 2021-04-05 | 개시 | Citigroup | Buy |
| 2020-06-29 | 개시 | Citigroup | Buy |
| 2020-06-29 | 개시 | Cowen | Outperform |
| 2020-06-29 | 개시 | Needham | Buy |
| 2020-06-29 | 개시 | Piper Sandler | Overweight |
모두보기
Pliant Therapeutics Inc 주식(PLRX)의 최신 뉴스
Price to earnings forward of Pliant Therapeutics, Inc. – DUS:9PT - TradingView
Pliant (PLRX) Watch: Finishes 1.74% Up at $1.17 at the Close; Technical View: the $1.11 to $1.23 Range Remains in Focus in the Available RecordUnusual Put Volume - vinanet.vn
symbol__ Stock Quote Price and Forecast - CNN
Why is Pliant Therapeutics stock climbing today? - Investing.com
Why is Pliant Therapeutics stock climbing today? By Investing.com - Investing.com India
Pliant Therapeutics (PLRX) Gains FDA Fast Track for PLN-101095 A - GuruFocus
Pliant Therapeutics receives FDA fast track for cancer drug - Investing.com
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors - The Manila Times
Pliant Therapeutics Receives FDA Fast Track Designation for - GlobeNewswire
J.P. Morgan Maintains Pliant Therapeutics(PLRX.US) With Sell Rating - Moomoo
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of "Reduce" by Brokerages - MarketBeat
Pliant wins FDA Fast Track status for PLN-101095 plus Keytruda in ICI-refractory solid tumors - Bitget
Pliant Therapeutics (PLRX) Advances Clinical Program Amidst Chal - GuruFocus
Monaco Asset Management SAM Purchases Shares of 1,938,747 Pliant Therapeutics, Inc. $PLRX - MarketBeat
Pliant Therapeutics Inc (FRA:9PT) Stock Price, Trades & News - GuruFocus
Pliant Therapeutics (PLRX) Slips to $1.07, Testing Critical Support ZoneMutual Fund Flow - dars.gov.et
Pliant Therapeutics (NASDAQ:PLRX) Downgraded by Wall Street Zen to Sell - MarketBeat
Pliant Therapeutics (PLRX) gains 8.9% institutional holder in ADAR1 Capital - Stock Titan
Pliant Therapeutics (PLRX): Citadel entities, Kenneth Griffin report 3.5% holding - Stock Titan
Pliant Therapeutics (PLRX) Institutional Ownership 2026 $PLRX - MarketBeat
Price performance - Yahoo Finance Australia
CCORF Maintains Pliant Therapeutics(PLRX.US) With Hold Rating, Maintains Target Price $3 - Moomoo
RBC Capital Sticks to Their Hold Rating for Pliant Therapeutics (PLRX) - The Globe and Mail
PLRX (Pliant Therapeutics) 12-1 Month Momentum % : -30.79% (As of Aug. 17, 2026) - GuruFocus
Form 8K Pliant Therapeutics Inc For: 11 August By Investing.com - Investing.com India
Pliant Therapeutics cuts Q2 loss to $22.4M on lower costs - scanx.trade
Pliant Therapeutics (NASDAQ:PLRX) Posts Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results - The Manila Times
Pliant Therapeutics (PLRX) halves quarterly loss and reports $159.6M in cash reserves - Stock Titan
BRIEF-Pliant Therapeutics Q2 Net Income USD -22.371 Million - TradingView
Pliant Therapeutics (PLRX) Earnings Date and Reports 2026 $PLRX - MarketBeat
Pliant Therapeutics Q1 2026 Earnings: Narrower Loss Beats Estimates as Fibrosis Pipeline AdvancesMargin Improvement Report - vinanet.vn
Pliant Therapeutics Inc (PLRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pliant Therapeutics Inc (PLRX) Stock News Today - TradingKey
Pliant Therapeutics, Inc. expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Pliant Therapeutics (PLRX) Expected to Release Quarterly Earnings on Thursday - MarketBeat
Pliant Therapeutics (PLRX) Holds Near Support Amid Modest DeclineLinear Regression - vinanet.vn
Pliant Therapeutics (PLRX) Edges Higher Amid Tight Trading Range — Key Levels in FocusStandard Deviation - dars.gov.et
Pliant Therapeutics Inc (PLRX) Income Statement - TradingKey
Pliant Therapeutics Inc (PLRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pliant Therapeutics Inc (PLRX) Cash Flow - TradingKey
Pliant Therapeutics Inc (PLRX) Balance Sheet - TradingKey
Pliant Therapeutics Inc (PLRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pliant Therapeutics (PLRX) Slides Near Support as Selling Pressure ContinuesInsider Sentiment - vinanet.vn
Pliant Therapeutics Inc (PLRX) Institutional Confidence - TradingKey
Pliant Therapeutics Inc (PLRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
PLRX|Pliant Therapeutics Inc|Price:1.080|Chg%:-0.010 - TradingKey
PLRX|Pliant Therapeutics Inc|Price:1.090|Chg%:+0.010 - TradingKey
Pliant Therapeutics Inc (PLRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pliant Therapeutics (PLRX) Holds Near Support as Biotech Stock Stalls at $1.08Block Trade Flow - vinanet.vn
Pliant Therapeutics (NASDAQ:PLRX) Trading Down 7%Here's Why - MarketBeat
Pliant Therapeutics Inc (PLRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Pliant Therapeutics Inc 주식 (PLRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Cheung Lily | Chief Human Resource Officer |
Jan 20 '26 |
Sale |
1.28 |
7,534 |
9,644 |
44,847 |
| Coulie Bernard | President and CEO |
Jan 20 '26 |
Sale |
1.28 |
89,375 |
114,400 |
505,601 |
| Kuo Minnie | Chief Operating Officer |
Jan 20 '26 |
Sale |
1.28 |
6,917 |
8,854 |
37,806 |
0.86%
0.31%
자본화:
|
볼륨(24시간):